Manufacturer
PFIZER (PERTH) PTY. LTD.
Contents
Epirubicin HCl
Indication
Breast, gastric, ovarian, small cell lung & superficial bladder (Tis, Ta) cancer, Non-Hodgkin's lymphoma, advanced/metastatic soft tissue sarcoma. Prophylaxis of recurrence after transurethral resection of stage T1 papillary & stage Ta multifocal papillary cancers (grade 2 & 3).
Instruction
75-90 mg/m2 single IV inj at 21-days intervals. Breast cancer 135 mg/m2 as a single & and 120 mg/m2 in combination every 3-4 wk. Adjuvant treatment of early breast cancer patient w/ +ve lymph nodes 100-120 mg/m2 every 3-4 wk. Intravesical Papillary transitional cell bladder carcinoma 8 wkly instillations of 50 mg. Prophylaxis of recurrences after transurethral resection of superficial tumours 4 wkly administrations of 50 mg followed by 11 mthly instillations at same dosage.
Drug interaction
Close monitoring of cardiac function w/ 5-fluorouracil, cyclophosphamide, cisplatin, taxanes, trastuzumab, Ca-channel blockers. Additive cardiotoxic effect w/ propranolol. Increased AUC by cimetidine. Increased plasma conc by paclitaxel. Enhanced myocardial toxicity w/ radiotherapy. Not to be mixed w/ heparin.
Malaysia
